InMode Stock May Be Riskier Than It Appears

 | Aug 02, 2023 12:45AM ET

InMode (NASDAQ:INMD) Ltd. is a $3.6B company that offers non- or minimally invasive aesthetic medical products in the US and internationally. Basically, if there’s something that you don’t like about your skin, but don’t feel like going under the scalpel either, InMode can probably help you. The company went public in 2019 at a split-adjusted price of $7 per share.

For some reason, INMD stock exceeded $99 in November 2021. EPS came in below $2 that year, meaning investors were willing to pay over 50 years’ worth of earnings for the shares. Euphoria doesn’t last long, though, and by mid-2022, InMode stock was down ~80% to the low-$20s. Currently, at $44, its valuation makes a lot more sense as the company is expected to earn roughly $2.70 a share in 2023.

On the other hand, revenue growth is decelerating and there’s margin erosion due to inflation. The company’s products are used in procedures that may be characterized as discretionary. In a recession, people will simply not be spending as much money on aesthetic medical procedures as they do in a healthy economy. So is InMode stock worth buying at a price-to-earnings ratio of 16? Elliott Wave analysis gives us a pause.